ATRC AtriCure, Inc.
AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally. It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. It also provides cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; cryoXT probes, a cryoablation device designed specifically for Cryo Nerve Block therapy; LARIAT System, a solution for soft-tissue closure; Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; and Subtle Cannula's to support access for EPi-Sense catheters. In addition, the company sells various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.…
Industry Peers
Medical Instruments & SuppliesKey Statistics
About AtriCure (NASDAQ: ATRC)
›
AtriCure (NASDAQ: ATRC) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Instruments & Supplies industry, part of the Healthcare sector, and reports about 1,350 employees.
The shares were at 54.11 USD on 19 November 2026, up 71.8% over 52 weeks. Its 52-week range is 25.37 USD to 66.02 USD: the price is 18.0% below the high and 113.3% above the low.
At a market capitalisation of 2.76B USD, it trades at 174.5 times trailing earnings and 119.3 times forward earnings. The median trailing P/E of its 19 largest Medical Instruments & Supplies peers is 49.2, a premium of 254% for ATRC.
AtriCure reports return on equity of -2.3%, an operating margin of 2.9% and revenue up 15.0% year over year.
It holds more cash than debt, a net cash position of 90.20M USD. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 9 analysts cover the stock, with an average rating of Buy; their mean price target of 64.89 USD is 19.9% above the current price. The next earnings report is expected on 16 February 2027.